AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Apr 5, 2021
31637_dirs_2021-04-05_6c863c91-ec11-4639-9d67-f6203a5aff8e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-04-01
Reporting Person: Tessier-Lavigne Marc (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-01 | Common Stock | S | 14223 | $55.606 | Disposed | 2628073 | Direct |
| 2021-04-01 | Common Stock | S | 29593 | $56.906 | Disposed | 2598480 | Direct |
| 2021-04-01 | Common Stock | S | 6184 | $57.595 | Disposed | 2592296 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.22 to $56.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 3,253 restricted stock units.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.23 to $57.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.23 to $58.095 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.